ChiCTR2100045998 版本V1.1 版本创建时间2021/12/05 21:17:42 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100045998 

最近更新日期:

Date of Last Refreshed on:

2021-12-05 21:16:11 

注册时间:

Date of Registration:

2021-05-02 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

凝固酶阴性葡萄球菌感染的新生儿万古霉素最佳暴露:基于病历记录的回顾性研究

Public title:

Optimal vancomycin exposure in neonates with coagulase negative staphylococcus infection: a retrospective study based on medical records

注册题目简写:

English Acronym:

研究课题的正式科学名称:

凝固酶阴性葡萄球菌感染的新生儿万古霉素最佳暴露:基于病历记录的回顾性研究

Scientific title:

Optimal vancomycin exposure in neonates with coagulase negative staphylococcus infection: a retrospective study based on medical records

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈权耀 

研究负责人:

陈权耀 

Applicant:

Chen Quanyao 

Study leader:

Chen Quanyao 

申请注册联系人电话:

Applicant telephone:

+86 18050194642

研究负责人电话:

Study leader's
telephone:

+86 18050194642

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

chenquanyao@outlook.com

研究负责人电子邮件:

Study leader's E-mail:

chenquanyao@outlook.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

厦门市思明区镇海路10号

研究负责人通讯地址:

厦门市思明区镇海路10号

Applicant address:

10 Zhenhai Road, Siming District, Xiamen, Fujian

Study leader's address:

10 Zhenhai Road, Siming District, Xiamen, Fujian

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

厦门大学附属妇女儿童医院

Applicant's institution:

Women and Children's Hospital, School of Medicine, Xiamen university

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY-2020-003

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

厦门市妇幼保健院人体研究伦理委员会

Name of the ethic committee:

Human Research Ethics Committee of Women and Children's Hospital, School of Medicine, Xiamen University

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

陈舒婷

Contact Name of the ethic committee:

Chen Shuting

伦理委员会联系地址:

福建省厦门市思明区镇海路10号

Contact Address of the ethic committee:

10 Zhenhai Road, Siming District, Xiamen, Fujian

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

厦门大学附属妇女儿童医院

Primary sponsor:

Women and Children's Hospital, School of Medicine, Xiamen university

研究实施负责(组长)单位地址:

厦门市思明区镇海路10号

Primary sponsor's address:

10 Zhenhai Road, Siming District, Xiamen, Fujian

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

福建

市(区县):

厦门

Country:

China

Province:

Fujian

City:

Xiamen

单位(医院):

厦门大学附属妇女儿童医院

具体地址:

思明区镇海路10号

Institution
hospital:

Women and Children's Hospital, School of Medicine, Xiamen university

Address:

10 Zhenhai Road, Siming District

经费或物资来源:

政府经费及单位自筹

Source(s) of funding:

Goverment scientific research funding and hospital self-funded

研究疾病:

感染  

Target disease:

Infection

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

本研究通过贝叶斯反馈,估算患儿万古霉素AUC,结合临床疗效及不良反应,探讨凝固酶阴性葡萄球菌感染患儿AUC的最佳靶值,为新生儿万古霉素个体化给药提供参考。  

Objectives of Study:

In our study, we used Bayesian feedback to estimate the AUC of vancomycin in neonates.Combined with clinical efficacy and adverse reactions, the optimal target value of AUC in neonates with coagulase-negative staphylococcal infection was investigated, so as to provide reference for individual administration of vancomycin in newborns.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

入院时产后日龄(PNA)≤28d;
患儿使用万古霉素治疗至少2天;
至少有一个可靠的万古霉素血药浓度监测值;
患儿人口统计学、血常规、血生化等临床资料完整。

Inclusion criteria

Postpartum age (PNA) ≤28 days at admission;
The neonate was treated with vancomycin for at least 2 days;
At least one serum concentration monitoring value of vancomycin;
Demography, blood routine, blood biochemical and other clinical data of the children were complete.

排除标准:

临床治疗过程中未使用万古霉素治疗感染;
患儿基本信息缺失,临床资料不完整;
患儿使用万古霉素治疗的时间少于2天;
未测定万古霉素血药浓度或血药浓度值超出检测限;
用药期间进行肾脏替代治疗者。

Exclusion criteria:

Vancomycin was not used to treat infection during clinical treatment.
The basic information of the neonate is missing, and the clinical data are incomplete.
The duration of treatment with vancomycin was less than 2 days.
Serum concentration of vancomycin was not determined or the serum concentration exceeded the detection limit;
Renal replacement therapy during medication.

研究实施时间:

Study execute time:

From 2021-05-01 00:00:00 To 2021-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-05-01 00:00:00 To 2021-12-31 00:00:00

干预措施:

Interventions:

组别:

病例系列报道

样本量:

153

Group:

case series

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

福建 

市(区县):

厦门 

Country:

China

Province:

Fujian

City:

Xiamen

单位(医院):

厦门大学附属妇女儿童医院 

单位级别:

三级甲等 

Institution
hospital:

Women and Children's Hospital, School of Medicine, Xiamen university

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

万古霉素血药浓度

指标类型:

主要指标

Outcome:

vancomycin serum concentration

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

人口统计学

指标类型:

主要指标

Outcome:

demographics

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血生化

指标类型:

主要指标

Outcome:

Blood biochemistry

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

主要指标

Outcome:

Blood routine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

病原学检查

指标类型:

主要指标

Outcome:

Etiological examination

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

最小抑菌浓度测定

指标类型:

主要指标

Outcome:

MIC measurement

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

合并用药

指标类型:

主要指标

Outcome:

combination

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 0 years
最大 Max age 0 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不涉及

Randomization Procedure (please state who generates the random number sequence and by what method):

not involved

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2022年12月31日前通过公共管理平台ResMan共享, http://www.medresman.org.cn.

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Before December 31, 2023 via ResMan, , http://www.medresman.org.cn.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集:病例记录表(CRF) 电子采集和管理系统:ResMan平台

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Digital collection:Case Record Form Data management:ResMan.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2021-05-02 05:17:05